Oak Ridge, TN, March 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) in three new hospitals through new analyzer purchases, and the utilization of Daxor’s ezBVA Lab service. These new acquisitions further fuel BVA sales growth and underscore its clinical relevance.

New client and services wins include:

• BVA analyzer purchase at a 735-bed non-profit, tertiary, research and academic medical center located in northern New Jersey.

• Daxor’s ezBVA Lab service extended to a regional academic medical center, Level I adult trauma center in Ohio.

• Daxor’s ezBVA Lab service extended to an academic, integrated health system located in South Carolina.
  

“Our sales and marketing teams have kicked off the new calendar year with great momentum, and these new account openings in the past two weeks are further evidence of the more rapid uptake of our diagnostic solutions,” said Michael Feldschuh, Daxor’s CEO and President. “We remain focused on commercialization - broadening our reach with new analyzer sales, while driving increased utilization within our current customer base, supported by our expanding ezBVA Lab service. The continued growth of our client base paves the way for further adoption of our next-generation systems set to launch in the near term.”

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.